Nephrotic Syndrome Diagnostics and Therapeutics Market
Nephrotic Syndrome Diagnostics and Therapeutics Market Size, Share & Trends Analysis by Diagnosis Tests (Urinalysis, Blood Tests, Kidney Biopsy, and Others) By Treatment (Blood Pressure Lowering Medications, Immune System-Suppressing Medications, Cholesterol-Reducing Medications, and Others), Forecast Period (2026-2035)
Industry Overview
Nephrotic syndrome diagnostics & therapeutics market was valued at $3.0 billion in 2025 and is projected to reach $6.5 billion by 2035, growing at a CAGR of 6.2% during the forecast Period (2026-2035). The market growth is driven by increasing incidences of chronic kidney diseases, the launch of targeted, non-steroidal therapies, and advanced, non-invasive diagnostic technologies.
Market Dynamics
Rising Prevalence of Kidney?Related Disorders and Comorbidities
A primary driver of market growth is the increasing global incidence of nephrotic syndrome, largely fueled by the rising prevalence of chronic kidney diseases (CKDs), diabetes mellitus, hypertension, obesity, and autoimmune conditions that contribute to kidney damage. Diabetes, for example, is a major risk factor for diabetic nephropathy, which can progress to nephrotic syndrome; higher diabetes rates therefore, expand the patient pool requiring both diagnostics and therapeutics. This growing disease burden is prompting greater demand for effective diagnostics and treatment solutions to manage proteinuria, control symptoms, and prevent progression to end?stage renal disease.
Advancements in Diagnostics and Targeted Therapeutics
Technological innovation in diagnostic methods and treatment options is another strong market driver. Improved diagnostic technologies such as enhanced urinalysis, advanced imaging, molecular biomarker tests, and more precise kidney biopsy techniques are enabling earlier and more accurate detection of nephrotic syndrome and its subtypes. Early diagnosis supports timely therapeutic intervention and better outcomes, which in turn drives market uptake. On the therapeutic front, novel biologics, targeted immunomodulators, and precision medicine approaches are increasingly adopted, offering improved safety and efficacy profiles compared with conventional corticosteroids and broad immunosuppressants.
Increasing Healthcare Awareness, Infrastructure, and Investments
Growth is also supported by rising healthcare awareness and improved infrastructure, especially in emerging economies. Public health initiatives, patient education programs, and screening campaigns are enhancing knowledge about kidney health, leading to increased screening rates and earlier management of nephrotic syndrome. Meanwhile, greater healthcare spending and investments in nephrology care, including research and development by pharmaceutical and biotech companies, are expanding access to advanced diagnostics and therapeutics. Expanding specialty care facilities, supportive regulatory policies for orphan drugs, and collaborations between industry and research networks further bolster innovation and uptake.
Market Segmentation
- Based on the diagnostic tests, the market is segmented into urinalysis, blood tests, kidney biopsy, and others.
- Based on the treatment, the market is segmented into blood pressure-lowering medications, immune system-suppressing medications, cholesterol-reducing medications, and Others.
Urinalysis Segment to Grow at a Considerable Market Share
Urinalysis emerges as the largest and most dominant segment overall, particularly within the diagnosis tests category, and plays a leading role in driving global market revenue and adoption. Urinalysis holds this position because it serves as the primary screening tool for detecting hallmark features of nephrotic syndrome, such as heavy proteinuria, which is a defining characteristic of the disease. It is widely used across hospitals, clinics, and diagnostic laboratories due to its cost?effectiveness, ease of use, non?invasive nature, and broad clinical relevance not only for nephrotic syndrome but also for related kidney disorders, diabetes, and metabolic complications, making it a frontline diagnostic choice globally. Urinalysis often acts as the first step in clinical evaluation, guiding physicians on whether more advanced tests (like blood tests or kidney biopsy) are needed and enabling timely intervention, a factor that significantly contributes to its large market share.
As a result, among all segmentation options by diagnosis and treatment, urinalysis consistently accounts for the largest share in the global nephrotic syndrome diagnostics market, reflecting its pivotal role in early disease detection, monitoring, and routine patient management globally.
Blood Pressure Lowering Medications (Angiotensin-Converting Enzyme (ACE) Inhibitors): A Key Segment in Market Growth
The ACE inhibitors segment emerges as the key treatment driver. ACE inhibitors are widely prescribed not only to manage hypertension but also to reduce proteinuria and provide renoprotective benefits, which are central therapeutic goals in nephrotic syndrome management. Because nephrotic syndrome often coexists with elevated blood pressure and progressive kidney damage, clinicians favor ACE inhibitors as foundational supportive therapy alongside immunomodulatory agents. Their extensive clinical use is backed by established guidelines and favorable safety profiles, contributing to broad adoption across both primary care and specialist nephrology settings. The prominence of ACE inhibitors in treatment protocols supports sustained demand and market growth, especially as the global burden of chronic kidney conditions continues to rise. This enduring role, combined with their integration into combination regimens, positions ACE inhibitors as the primary growth segment among the treatment options for nephrotic syndrome.
Regional Outlook
The global nephrotic syndrome diagnostics & therapeutics market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).
North America Region to Hold a Substantial Growth Rate
In North America, the US dominates the global nephrotic syndrome diagnostics & therapeutics market, holding a major share due to its highly advanced healthcare infrastructure, extensive clinical research activity, and robust investment in both diagnostics and therapeutic innovation for kidney diseases. The US market benefits from widespread access to cutting?edge diagnostic technologies, early adoption of novel therapeutics, and comprehensive insurance frameworks that support treatment uptake.
These factors combine to establish the US as the key contributor to global market value and growth momentum. High prevalence rates of chronic kidney conditions that predispose patients to nephrotic syndrome further augment demand for both diagnostic services and therapeutic interventions. Additionally, substantial pharmaceutical research and development efforts focused on rare kidney disorders, coupled with favorable regulatory environments for new drug approvals, reinforce the US leadership position. While other regions, such as Europe and the Asia Pacific, are growing rapidly, the scale and maturity of the US nephrotic syndrome market continue to set it apart as the dominant national market globally.
Market Players Outlook
The major companies operating in the global nephrotic syndrome diagnostics & therapeutics market include Aurinia Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., Travere Therapeutics, Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions to expand their businesses and develop innovative products to maintain their market positioning.
Recent Development
- In November 2025, the FDA approved Voyxact (sibeprenlimab-szsi) injection for reducing proteinuria in adults with primary immunoglobulin A nephropathy (IgAN). IgAN is a serious kidney disease caused by the deposition of immunoglobulin A, leading to inflammation, damage, and potential kidney failure. The approval follows a randomized trial demonstrating that patients receiving Voyxact experienced a 50% reduction in proteinuria after 9 months, compared to a 2% increase in the placebo group.
- In October 2025, the FDA approved Roche’s Gazyva/Gazyvaro (obinutuzumab) for treating adult patients with active lupus nephritis, demonstrating superiority over standard therapy in phase II NOBILITY and phase III REGENCY studies. It is the only anti-CD20 monoclonal antibody to show complete renal response benefits in a randomized phase III trial. The drug can be administered after an initial four doses in the first year, with a shorter infusion time for eligible patients, making it more convenient. In the REGENCY study, 46.4% of patients receiving Gazyva/Gazyvaro achieved a complete renal response compared to 33.1% on standard therapy alone, alongside improvements in various disease markers. Its safety profile aligns with known effects from previous oncology uses.
The Report Covers
- Market value data analysis for 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global nephrotic syndrome diagnostics & therapeutics market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Nephrotic Syndrome Diagnostics & Therapeutics Market Sales Analysis – Diagnosis Tests| Treatment ($ Million)
- Nephrotic Syndrome Diagnostics & Therapeutics Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Nephrotic Syndrome Diagnostics & Therapeutics Market Trends
- Market Recommendations
- Porter's Five Forces Analysis for the Nephrotic Syndrome Diagnostics & Therapeutics Market
- Competitive Rivalry
- Threat of New Entrants
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Market Determinants
- Market Drivers
- Drivers For Global Nephrotic Syndrome Diagnostics & Therapeutics Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Global Nephrotic Syndrome Diagnostics & Therapeutics Market: Impact Analysis
- Market Opportunities
- Opportunities For Global Nephrotic Syndrome Diagnostics & Therapeutics Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Nephrotic Syndrome Diagnostics & Therapeutics Market Revenue and Share by Manufacturers
- Nephrotic Syndrome Diagnostics & Therapeutics Product Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- Aurinia Pharmaceuticals Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Hoffmann-La Roche Ltd.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Novartis AG
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Pfizer Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Travere Therapeutics, Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- Aurinia Pharmaceuticals Inc.
- Key Company Analysis
- Global Nephrotic Syndrome Diagnostics & Therapeutics Market Sales Analysis by Diagnosis Tests ($ Million)
- Urinalysis
- Blood Tests
- Kidney Biopsy
- Others (CT Scan, Renal Ultra-Sonography)
- Global Nephrotic Syndrome Diagnostics & Therapeutics Market Sales Analysis by Treatment ($ Million)
- Blood Pressure Lowering Medications
- Angiotensin-Converting Enzyme (ACE) Inhibitors
- Angiotensin Receptor Blockers (ARBs)
- Others (Renin Inhibitors and Benazepril)
- Immune System-Suppressing Medications
- Cholesterol-Reducing Medications
- Others (Blood Thinners)
- Blood Pressure Lowering Medications
- Regional Analysis
- North American Nephrotic Syndrome Diagnostics & Therapeutics Market Sales Analysis – Diagnosis Tests | Treatment | Country ($ Million)
- Macroeconomic Factors for North America
- United States
- Canada
- European Nephrotic Syndrome Diagnostics & Therapeutics Market Sales Analysis – Diagnosis Tests | Treatment | Country ($ Million)
- Macroeconomic Factors for Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific Nephrotic Syndrome Diagnostics & Therapeutics Market Sales Analysis – Diagnosis Tests | Treatment | Country ($ Million)
- Macroeconomic Factors for Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- Rest of Asia-Pacific
- Rest of the World Nephrotic Syndrome Diagnostics & Therapeutics Market Sales Analysis – Diagnosis Tests | Treatment | Country ($ Million)
- Macroeconomic Factors for the Rest of the World
- Latin America
- Middle East and Africa
- Company Profiles
- Abbott Laboratories
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AbbVie Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Aldeyra Therapeutics, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Alembic Pharmaceuticals
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Asahi Kasei Pharma Corp.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AstraZeneca
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Aurinia Pharmaceuticals Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bristol-Myers Squibb Co.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Chugai Pharmaceutical Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Eli Lilly and Co.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Hoffmann-La Roche AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- GlaxoSmithKline plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Mallinckrodt PLC
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Novartis AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Otsuka Pharmaceutical Co. Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Pfizer Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sanofi
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Travere Therapeutics, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Vera Therapeutics
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Vertex Pharmaceuticals
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Abbott Laboratories
1. Global Nephrotic Syndrome Diagnostics & Therapeutics Market Research and Analysis by Diagnosis Tests, 2025–2035 ($ Million)
2. Global Urinalysis For Nephrotic Syndrome Diagnostics & Therapeutics Market Research And Analysis By Region, 2025–2035 ($ Million)
3. Global Blood Tests For Nephrotic Syndrome Diagnostics & Therapeutics Market Research And Analysis By Region, 2025–2035 ($ Million)
4. Global Kidney Biopsy For Nephrotic Syndrome Diagnostics & Therapeutics Market Research And Analysis By Region, 2025–2035 ($ Million)
5. Global Other Diagnosis Tests Nephrotic Syndrome Diagnostics & Therapeutics Market Research And Analysis By Region, 2025–2035 ($ Million)
6. Global Nephrotic Syndrome Diagnostics & Therapeutics Market Research and Analysis by Treatment, 2025–2035 ($ Million)
7. Global Blood Pressure Lowering Medications Market Research And Analysis By Region, 2025–2035 ($ Million)
8. Global Angiotensin-Converting Enzyme (ACE) Inhibitors Market Research And Analysis By Region, 2025–2035 ($ Million)
9. Global Angiotensin Receptor Blockers (ARBs) Market Research And Analysis By Region, 2025–2035 ($ Million)
10. Global Others (Renin Inhibitors and Benazepril) Market Research And Analysis By Region, 2025–2035 ($ Million)
11. Global Immune System-Suppressing Medications Market Research And Analysis By Region, 2025–2035 ($ Million)
12. Global Cholesterol-Reducing Medications Market Research And Analysis By Region, 2025–2035 ($ Million)
13. Global Other Treatment Nephrotic Syndrome Diagnostics & Therapeutics Market Research And Analysis By Region, 2025–2035 ($ Million)
14. Global Nephrotic Syndrome Diagnostics & Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
15. North American Nephrotic Syndrome Diagnostics & Therapeutics Market Research and Analysis by Diagnosis Tests, 2025–2035 ($ Million)
16. North American Nephrotic Syndrome Diagnostics & Therapeutics Market Research and Analysis by Treatment, 2025–2035 ($ Million)
17. European Nephrotic Syndrome Diagnostics & Therapeutics Market Research and Analysis by Diagnosis Tests, 2025–2035 ($ Million)
18. European Nephrotic Syndrome Diagnostics & Therapeutics Market Research and Analysis by Treatment, 2025–2035 ($ Million)
19. Asia-Pacific Nephrotic Syndrome Diagnostics & Therapeutics Market Research and Analysis by Diagnosis Tests, 2025–2035 ($ Million)
20. Asia-Pacific Nephrotic Syndrome Diagnostics & Therapeutics Market Research and Analysis by Treatment, 2025–2035 ($ Million)
21. Rest of the World Nephrotic Syndrome Diagnostics & Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
22. Rest of the World Nephrotic Syndrome Diagnostics & Therapeutics Market Research and Analysis by Diagnosis Tests, 2025–2035 ($ Million)
23. Rest of the World Nephrotic Syndrome Diagnostics & Therapeutics Market Research and Analysis by Treatment, 2025–2035 ($ Million)
1. Global Nephrotic Syndrome Diagnostics & Therapeutics Market Share By Diagnosis Tests, 2025 Vs 2035 (%)
2. Global Urinalysis For Nephrotic Syndrome Diagnostics & Therapeutics Market Share By Region, 2025 Vs 2035 (%)
3. Global Blood Tests For Nephrotic Syndrome Diagnostics & Therapeutics Market Share By Region, 2025 Vs 2035 (%)
4. Global Kidney Biopsy For Nephrotic Syndrome Diagnostics & Therapeutics Market Share By Region, 2025 Vs 2035 (%)
5. Global Other Diagnosis Tests For Nephrotic Syndrome Diagnostics & Therapeutics Market Share By Region, 2025 Vs 2035 (%)
6. Global Nephrotic Syndrome Diagnostics & Therapeutics Market Share By Treatment, 2025 Vs 2035 (%)
7. Global Blood Pressure-Lowering Medications Market Share By Region, 2025 Vs 2035 (%)
8. Global Angiotensin-Converting Enzyme (ACE) Inhibitors Market Share By Region, 2025 Vs 2035 (%)
9. Global Angiotensin Receptor Blockers (Arbs) Market Share By Region, 2025 Vs 2035 (%)
10. Global Others (Renin Inhibitors and Benazepril) Market Share By Region, 2025 Vs 2035 (%)
11. Global Immune System-Suppressing Medications Market Share By Region, 2025 Vs 2035 (%)
12. Global Cholesterol-Reducing Medications Market Share By Region, 2025 Vs 2035 (%)
13. Global Other Treatments For Nephrotic Syndrome Diagnostics & Therapeutics Market Share By Region, 2025 Vs 2035 (%)
14. Global Nephrotic Syndrome Diagnostics & Therapeutics Market Share By Region, 2025 Vs 2035 (%)
15. US Nephrotic Syndrome Diagnostics & Therapeutics Market Size, 2025–2035 ($ Million)
16. Canada Nephrotic Syndrome Diagnostics & Therapeutics Market Size, 2025–2035 ($ Million)
17. UK Nephrotic Syndrome Diagnostics & Therapeutics Market Size, 2025–2035 ($ Million)
18. France Nephrotic Syndrome Diagnostics & Therapeutics Market Size, 2025–2035 ($ Million)
19. Germany Nephrotic Syndrome Diagnostics & Therapeutics Market Size, 2025–2035 ($ Million)
20. Italy Nephrotic Syndrome Diagnostics & Therapeutics Market Size, 2025–2035 ($ Million)
21. Spain Nephrotic Syndrome Diagnostics & Therapeutics Market Size, 2025–2035 ($ Million)
22. Russia Nephrotic Syndrome Diagnostics & Therapeutics Market Size, 2025–2035 ($ Million)
23. Rest of Europe Nephrotic Syndrome Diagnostics & Therapeutics Market Size, 2025–2035 ($ Million)
24. India Nephrotic Syndrome Diagnostics & Therapeutics Market Size, 2025–2035 ($ Million)
25. China Nephrotic Syndrome Diagnostics & Therapeutics Market Size, 2025–2035 ($ Million)
26. Japan Nephrotic Syndrome Diagnostics & Therapeutics Market Size, 2025–2035 ($ Million)
27. South Korea Nephrotic Syndrome Diagnostics & Therapeutics Market Size, 2025–2035 ($ Million)
28. Australia and New Zealand Nephrotic Syndrome Diagnostics & Therapeutics Market Size, 2025–2035 ($ Million)
29. ASEAN Economies Nephrotic Syndrome Diagnostics & Therapeutics Market Size, 2025–2035 ($ Million)
30. Rest of Asia-Pacific Nephrotic Syndrome Diagnostics & Therapeutics Market Size, 2025–2035 ($ Million)
31. Latin America Nephrotic Syndrome Diagnostics & Therapeutics Market Size, 2025–2035 ($ Million)
32. Middle East and Africa Nephrotic Syndrome Diagnostics & Therapeutics Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of user within the company
Contact Sales
